Type of document : Magazine article Edition cipher : Author(s) : Bilous N., Abramenko I., Chumak A., Dyagil I., Martina Z. Title : Analysis of LPL gene expression in patients with chronic lymphocytic leukemia Place of publication : Экспериментальная онкология. - 2019. - Т. 41, № 1. - С. 39-45 (Cipher ЕУ12/2019/41/1) Notes : Bibliogr. at the end of the art. Annotation: The IGHV mutational status is one of the most important markers for chronic lymphocytic leukemia (CLL) prognostication. Lipoprotein lipase (LPL) gene expression was found to correlate with IGHV status and was suggested as its surrogate marker. Recent data reported that LPL expression might be influenced by pivotal signalling pathways in CLL. This study aimed to assess LPL gene expression in relation to key immunogenetic and molecular markers of CLL, including IGHV mutational status, B-cell receptor (BCR) stereotypy, TP53, NOTCH1, and SF3B1 gene mutations. Materials and Methods: Expression of LPL mRNA was measured in peripheral blood mononuclear cells of 73 CLL patients by real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR). IGHV, NOTCH1, TP53, and SF3B1 gene mutation analysis was performed by PCR amplification and direct sequencing. Results: 44 of 73 (60%) CLL cases were categorized as LPL-positive based on the cut-off value established by ROC (receiver operating characteristic) curve analysis. LPL expression was significantly associated with IGHV mutation status (r = 0.684; p 0.0001) and tended to correlate with presence of NOTCH1 gene mutations (p Additional Access Points: Bilous, N. Abramenko, I. Chumak, A. Dyagil, I. Martina, Z.